May 14th 2024
In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes.
Q&A With Miruna Sasu, president and CEO, COTA, Inc.
April 20th 2022From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.
Q&A With Ignacio Medina, founder, Zetta Genomics
March 24th 2022Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.
The Resilience of R&D: Pharma Posted Record Output in 2021
March 8th 2022Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.
Bringing New Solutions into View for Cell and Gene Therapies: Masahide Goto, President, AIRM
January 31st 2022Masahide Goto outlines the world of the Astellas Institute for Regenerative Medicine (AIRM), which serves as the company’s global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options.
Shining a Light on Rare Disease: Evidence Challenges and Solutions
January 19th 2022Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
2022 Pipeline Report: Capitalizing on Opportunity
December 9th 2021Our annual report takes a look at pharma’s current investment in drug development, which this year demonstrates a focus on five important therapeutic areas of interest—Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids.